MedWatch

Almirall predicts positive 2021 development of psoriasis product

Dermatology company Almirall retreated in 2020 due to generic competition and Covid-19-related challenges, but the firm expects progress in 2021, aided by two of the firm's newest products.

Photo: Mikkel Aabenhus Hemmingsen / MedWatch

In early 2020, already, Almirall warned this wouldn't be the best year. Competition from US generic products would have a severe impact, and the firm was facing a series of investments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Latest news

See all jobs